COMPANY

Nacuity Pharmaceuticals

The company is developing targeted, prescription antioxidant therapies that aim to stop chemically aggressive oxygen molecules from damaging tissue. From company website Source · Oct 13, 2026

Keywords: molecules Retinitis Pigmentosa Usher Syndrome Cataract Usher Syndromes Cystinosis NPI-001 N-acetylcysteine amide

Profile checked Oct 10, 2026

5Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $8.39M (Form D filed Dec 30, 2025). SEC Form D 0001690279-25-000002 (Dec 30, 2025)
Evidence (1 event)
- Dec 30, 2025 · SEC Form D 0001690279-25-000002
  Name of Issuer: Nacuity Pharmaceuticals, Inc.; CIK: 1690279; Address: Fort Worth, TX; Submission type: D; Filing date: 2025-12-30; Industry Group: Pharmaceuticals; Date of First Sale: 2025-12-11; Types of Securities Offered: Equity, Debt, Option/warrant, Security to be acquired, Other (Convertible Promissory Notes convertible into preferred stock or common stock, Common Stock Purchase Warrants, Common Stock issued for Warrant Conversion); Business combination transaction: false; Total Offering Amount: 30000000; Total Amount Sold: 8393350; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Timeline

2026-12 Trial start Phase 3: 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome source ↗
2026-08 Trial start Phase 3: A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome source ↗
Oct 29, 2023 Trial start Phase 1/Phase 2: PK and PD Study of NPI-001 and Cysteamine Bitartrate source ↗
Jan 27, 2022 Trial start Phase 1/Phase 2: NPI-002 Intravitreal Implant for the Delay of Cataract Progression source ↗
Sep 3, 2020 Trial start Phase 1/Phase 2: Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome source ↗

Upcoming milestones

2029-02 (ESTIMATED) · Phase 3 · A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome · NCT07710196
2029-07 (ESTIMATED) · Phase 3 · 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome · NCT07290530

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 5

Record	Title	Phase	Status	Start	Primary completion
NCT05026632	NPI-002 Intravitreal Implant for the Delay of Cataract Progression	Phase 1/Phase 2	Completed	Jan 27, 2022	Sep 3, 2026 (actual)
NCT07710196	A 24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome	Phase 3	Not yet recruiting	2026-08	2029-02 (estimated)
NCT04355689	Safety and Efficacy of NPI-001 Tablets for RP Associated With Usher Syndrome	Phase 1/Phase 2	Completed	Sep 3, 2020	Jun 20, 2025 (actual)
NCT07290530	24-Month Trial of NPI-001 for the Preservation of Photoreceptors in Retinitis Pigmentosa Associated With Usher Syndrome	Phase 3	Not yet recruiting	2026-12	2029-07 (estimated)
NCT05994534	PK and PD Study of NPI-001 and Cysteamine Bitartrate	Phase 1/Phase 2	Active, not recruiting	Oct 29, 2023	2026-08 (estimated)